Because CDH6 is upregulated in endometrial cancer, gastric cancer, ovarian cancer, pancreatic cancer, papillary thyroid cancer and renal cell carcinoma, CLDN6-targeting ADCs, such as CUSP06 (AMT-707), HKT288 and raludotatug deruxtecan (R-DXd or DS-6000a), have been developed for the treatment of cancer (Bialucha et al., 2017; Patel et al., 2025; Suzuki et al., 2024). This evidence concerns the gene CDH6 and ovarian carcinoma.